Eversept Partners LP Sells 1,131,005 Shares of Evolus, Inc. $EOLS

Eversept Partners LP lessened its position in Evolus, Inc. (NASDAQ:EOLS) by 76.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 344,104 shares of the company’s stock after selling 1,131,005 shares during the period. Eversept Partners LP’s holdings in Evolus were worth $2,288,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of EOLS. Braidwell LP bought a new stake in Evolus in the fourth quarter valued at approximately $20,650,000. Nantahala Capital Management LLC increased its stake in Evolus by 33.2% in the third quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company’s stock valued at $35,163,000 after purchasing an additional 1,428,931 shares in the last quarter. Soleus Capital Management L.P. increased its stake in Evolus by 96.4% in the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after purchasing an additional 1,039,842 shares in the last quarter. Armistice Capital LLC bought a new stake in Evolus in the fourth quarter valued at approximately $6,490,000. Finally, Caligan Partners LP increased its stake in Evolus by 23.8% in the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after purchasing an additional 796,973 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. BTIG Research reissued a “buy” rating and set a $13.00 price objective on shares of Evolus in a research report on Wednesday. Finally, Wall Street Zen downgraded shares of Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Insiders Place Their Bets

In related news, insider David Moatazedi sold 13,669 shares of the firm’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $4.75, for a total value of $64,927.75. Following the completion of the transaction, the insider owned 604,700 shares of the company’s stock, valued at approximately $2,872,325. This trade represents a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.00% of the company’s stock.

Evolus Stock Up 1.7%

Shares of EOLS stock opened at $6.74 on Thursday. The firm has a fifty day moving average of $5.87 and a 200-day moving average of $5.55. Evolus, Inc. has a 12-month low of $3.86 and a 12-month high of $10.20. The company has a market capitalization of $443.90 million, a price-to-earnings ratio of -10.06 and a beta of 1.34.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $73.14 million for the quarter, compared to the consensus estimate of $72.52 million. During the same period last year, the company earned ($0.30) earnings per share. On average, equities analysts expect that Evolus, Inc. will post -0.38 EPS for the current year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.